Every Form 4 that Passage Bio, Inc. (PASG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PASG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PASG filings page.
Lynx1 Master Fund LP, an entity associated with Lynx1 Capital Management LP and Weston Nichols, purchased 50,055 shares of Passage BIO, Inc. common stock in an open-market transaction. The weighted average purchase price was $4.1175 per share, with individual trades between $3.33 and $4.30 per share.
Following this transaction, the entity’s indirect holdings reported for Passage BIO increased to 673,759 shares of common stock. Lynx1 Capital Management LP and Mr. Nichols each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
Passage BIO, Inc. director Sondhi Dolan received a grant of stock options covering 10,539 shares of common stock. The options have an exercise price of $5.0800 per share and expire on May 19, 2036. Following this grant, Dolan holds options for 10,539 shares directly.
The stock option vests in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or the company’s 2027 annual meeting of stockholders, as long as Dolan continues serving the company through that time.
Passage BIO director Derrell Porter received a new stock option grant. The award covers 10,539 options to buy Passage BIO common stock at an exercise price of $5.0800 per share, expiring on May 19, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.
Passage BIO, Inc. director Thomas Richard Kassberg received a grant of stock options covering 10,539 shares of common stock. The options have an exercise price of $5.08 per share and expire on May 19, 2036. They vest in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or the company’s 2027 annual stockholders’ meeting, subject to his continued service. Following this award, he holds 10,539 options directly.
Passage BIO director Sandip Kapadia received a new stock option grant. On May 19, 2026, he was granted options to acquire 10,539 shares of Passage BIO common stock at an exercise price of $5.08 per share, with no cash paid for the grant itself.
The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting, as long as he remains in continuous service. Following this award, Kapadia holds 10,539 director stock options directly, all expiring on May 19, 2036.
Passage BIO, Inc. director Maxine Gowen received a grant of stock options on May 19, 2026. The award covers 10,539 options, each giving the right to buy one share of common stock at an exercise price of $5.08 per share.
The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual stockholder meeting, as long as she continues serving the company through that date. After this grant, she holds options on 10,539 shares directly, which expire on May 19, 2036.
Passage BIO, Inc. director Athena Countouriotis received a grant of stock options covering 10,539 shares of common stock. The options have an exercise price of $5.0800 per share and expire on May 19, 2036.
The option vests in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of stockholders, as long as she continues serving the company through that date. After this grant, she holds 10,539 options directly.
Passage BIO, Inc. reported that CFO Kathleen Borthwick received an employee stock option grant covering 15,610 shares of common stock. The option has an exercise price of $7.64 per share and expires on March 16, 2035.
The award vests as to 1/48 of the total shares each month beginning on April 16, 2026, so long as she continues providing service on each vesting date. Following this grant, she holds stock options for 15,610 shares directly.
Passage BIO, Inc. reported that President and CEO William Chou received a grant of employee stock options for 58,000 shares of common stock at an exercise price of $7.64 per share. The options vest in equal monthly installments over 48 months beginning on April 16, 2026 and expire on March 16, 2035. This grant is a compensation award, not an open-market purchase or sale, and leaves Chou holding 58,000 options following the transaction.
Passage BIO, Inc. reported an insider equity transaction by President and CEO William Chou. On January 8, 2026, 10,000 restricted stock units converted into an equal number of common shares at an exercise price of $0. In connection with this vesting, 4,076 common shares were sold at a weighted average price of $18.4394 per share as part of an issuer-mandated "sell to cover" transaction to satisfy tax withholding obligations, rather than a discretionary sale.
After these transactions, Chou directly held 6,524 common shares and 10,000 RSUs. The RSUs vest in two equal installments, with 50% scheduled to vest on January 8, 2026 and the remaining 50% on January 8, 2027, subject to continued service with Passage BIO.
Passage BIO, Inc. CFO Kathleen Borthwick reported the vesting of equity awards and an associated tax sale. On January 8, 2026, 5,000 restricted stock units converted into common stock at an exercise price of $0, reflecting previously granted compensation.
On the same date, she sold 2,062 shares of common stock at a weighted average price of $18.4394 per share, in an issuer-mandated “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting. The price for these shares came from multiple trades between $18.13 and $19.3061 per share. After these transactions, she directly held 5,402 shares of common stock and 5,000 RSUs.